

Amendments to the Claims

Please amend the claims as follows. Applicant presents a full set of claims showing markups of the claims with insertions and deletions indicated by underlining and strikethrough text (or double bracketing), respectively.

1.-11. (Canceled)

12. (Currently amended) A method for treating cancer, comprising administering to a subject having a cancer characterized by reduced or absent LKB1 activity an effective amount of a compound that increases AMP-activated protein kinase (AMPK) activity in ~~(cells of)~~ the subject or in cells thereof.

13.-16. (Canceled)

17. (Original) The method of claim 12, wherein the compound is metformin or an analog or derivative thereof that increases AMPK activity.

18.-20. (Canceled)

21. (Currently amended) The method of claim 12, wherein the reduction of LKB1 activity is due to ~~[[the]]~~ a mutation or deletion of the LKB1 gene.

22. (Currently amended) The method of claim 12, further comprising subjecting the cancer ~~(cells)~~ of the subject or cells thereof to a cell death stimulus.

23.-30. (Canceled)

31. (Original) A method for promoting apoptosis of cells having reduced or absent LKB1 activity, comprising

contacting the cells with a compound that is an activator of AMP-activated protein kinase (AMPK).

32.-35. (Canceled)

36. (Original) The method of claim 31, wherein the compound is metformin or an analog or derivative thereof that increases AMPK activity.

37.-39. (Canceled)

40. (Currently amended) The method of claim 31, wherein the reduction of LKB1 activity is due to [[the]] a mutation or deletion of the LKB1 gene.

41.-70. (Canceled)

71. (Previously presented) A method of treating cancer comprising administering to a subject having a cancer characterized by reduced or absent LKB1 activity an effective amount of phenformin.

72. (Previously presented) A method for promoting apoptosis of cells having reduced or absent LKB1 activity comprising contacting the cells with phenformin.